

## Special Issue

# Advanced Research of Targeting CDKs in Oncology

### Message from the Guest Editor

Cyclin-dependent kinases (CDKs) are cell cycle key regulators overexpressed and deemed as therapeutic targets in many cancer types. CDK proteins lead to G1/S progression through phosphorylation of Rb facilitating tumorigenesis. The first clinically approved CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) have uncovered the great importance of targeting this pathway, demonstrating efficacy, but the identification of predictive biomarkers and the mechanisms underlying drug resistance still represent major unmet clinical needs. Moreover, new therapeutic approaches of combination therapy are emerging as a hot topic in this context to overcome resistance and should be explored. This Special Issue welcomes both basic studies and translational research including original articles, short communications, reviews, and commentaries, focused on anticancer strategies against CDKs. Special attention will be given to manuscripts reporting the molecular mechanisms of drug resistance, predictive biomarkers, and new therapeutic approaches in targeting CDK pathway in cancer.

### Guest Editor

Dr. Sara Ravaoli

Biosciences Laboratory, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy

### Deadline for manuscript submissions

closed (31 May 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/116996](https://mdpi.com/si/116996)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).